Inovio Pharmaceuticals, Inc.
As of Oct 22, 2026, Inovio Pharmaceuticals is in Stage 1, the basing phase, now in week 7 (since Sep 4, 2026). It closed at $0.84, 67.7% below its 52-week high and below its 200-day average, which is falling.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human pap… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is INO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
INO among Biotechnology406th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …406 | INO | Stage 1 · wk 7 | 17 | −32.8% |
Inovio Pharmaceuticals: quick answers
What stage is Inovio Pharmaceuticals in?
As of Oct 22, 2026, Inovio Pharmaceuticals (INO) is in Stage 1, the basing phase. It entered Stage 1 on Sep 4, 2026 and is in week 7. What the four stages mean
Is Inovio Pharmaceuticals in an uptrend?
Not yet. Inovio Pharmaceuticals is in Stage 1, a base that can come before an uptrend. It trades 34.7% below its 200-day average, which is falling.
How far is Inovio Pharmaceuticals from its 52-week high?
Inovio Pharmaceuticals closed at $0.84 on Oct 22, 2026, 67.7% below its 52-week high of $2.60. Its 52-week low is $0.66.
How has Inovio Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Inovio Pharmaceuticals is down 63.9% over the past year and down 50.3% so far in 2026.
Which sector and industry is Inovio Pharmaceuticals in?
Inovio Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.